<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Site-specific risk of second primary malignancy according to treatment of Hodgkin lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Site-specific risk of second primary malignancy according to treatment of Hodgkin lymphoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Site-specific risk of second primary malignancy according to treatment of Hodgkin lymphoma</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="8" width="10%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Site</td> <td class="subtitle1" colspan="4">Chemotherapy only</td> <td class="subtitle1" colspan="4">Chemotherapy plus radiotherapy</td> </tr> <tr> <td class="subtitle2"># of patients</td> <td class="subtitle2">SIR</td> <td class="subtitle2">95% CI</td> <td class="subtitle2">AER</td> <td class="subtitle2"># of patients</td> <td class="subtitle2">SIR</td> <td class="subtitle2">95% CI</td> <td class="subtitle2">AER</td> </tr> <tr> <td>All malignancies, except nonmelanoma skin cancer and Hodgkin lymphoma*</td> <td>157</td> <td>2.0<sup>¶</sup></td> <td>1.7 to 2.4</td> <td>32.9</td> <td>302</td> <td>3.9<sup>¶</sup></td> <td>3.5 to 4.4</td> <td>65.3</td> </tr> <tr> <td>Lung</td> <td>40</td> <td>2.9<sup>¶</sup></td> <td>2.0 to 3.9</td> <td>10.7</td> <td>60</td> <td>5.1<sup>¶</sup></td> <td>3.8 to 6.5</td> <td>14.0</td> </tr> <tr> <td>Non-Hodgkin lymphoma</td> <td>31</td> <td>11.5<sup>¶</sup></td> <td>7.8 to 16.3</td> <td>11.6</td> <td>51</td> <td>17.1<sup>¶</sup></td> <td>12.7 to 22.5</td> <td>13.9</td> </tr> <tr> <td>Leukemia, excluding CLL</td> <td>33</td> <td>26.7<sup>¶</sup></td> <td>18.4 to 37.5</td> <td>13.0</td> <td>42</td> <td>30.6<sup>¶</sup></td> <td>22.1 to 41.4</td> <td>11.8</td> </tr> <tr> <td>Leukemia</td> <td>33</td> <td>18.4<sup>¶</sup></td> <td>12.7 to 25.9</td> <td>12.8</td> <td>42</td> <td>22.7<sup>¶</sup></td> <td>16.3 to 30.7</td> <td>11.7</td> </tr> <tr> <td>Nonmelanoma skin cancer</td> <td>6</td> <td>0.5</td> <td>0.2 to 1.0</td> <td>–2.8</td> <td>30</td> <td>2.4<sup>¶</sup></td> <td>1.6 to 3.4</td> <td>5.1<sup>Δ</sup></td> </tr> <tr> <td>Breast (female)</td> <td>5</td> <td>0.5</td> <td>0.2 to 1.2</td> <td>–1.8</td> <td>30</td> <td>2.4<sup>¶</sup></td> <td>1.6 to 3.4</td> <td>5.1<sup>Δ</sup></td> </tr> <tr> <td>Unspecified primary</td> <td>2</td> <td>0.5</td> <td>0.1 to 1.9</td> <td>–0.7</td> <td>16</td> <td>4.7<sup>¶</sup></td> <td>2.7 to 7.6</td> <td>3.7</td> </tr> <tr> <td>Colon, rectum</td> <td>10</td> <td>1.1</td> <td>0.5 to 1.9</td> <td>0.2</td> <td>17</td> <td>2.0<sup>◊</sup></td> <td>1.2 to 3.2</td> <td>2.4</td> </tr> <tr> <td>Esophagus</td> <td>1</td> <td>0.5</td> <td>0.01 to 2.9</td> <td>–0.4</td> <td>7</td> <td>4.1<sup>§</sup></td> <td>1.6 to 8.4</td> <td>1.5</td> </tr> <tr> <td>Stomach</td> <td>4</td> <td>1.1</td> <td>0.3 to 2.9</td> <td>0.2</td> <td>8</td> <td>2.7<sup>◊</sup></td> <td>1.2 to 5.3</td> <td>1.5</td> </tr> <tr> <td>Soft tissue</td> <td>0</td> <td>0</td> <td>0 to 7.9</td> <td>–0.2</td> <td>5</td> <td>8.9<sup>¶</sup></td> <td>2.9 to 20.7</td> <td>1.3</td> </tr> <tr> <td>Melanoma</td> <td>1</td> <td>0.5</td> <td>0.01 to 2.8</td> <td>–0.4</td> <td>7</td> <td>2.7<sup>◊</sup></td> <td>1.1 to 5.5</td> <td>1.3</td> </tr> <tr> <td>Tongue, mouth, pharynx</td> <td>2</td> <td>1.3</td> <td>0.2 to 4.6</td> <td>0.2</td> <td>6</td> <td>3.5<sup>◊</sup></td> <td>1.3 to 7.7</td> <td>1.2</td> </tr> <tr> <td>Nervous system</td> <td>3</td> <td>1.2</td> <td>0.2 to 3.5</td> <td>0.2</td> <td>7</td> <td>2.3</td> <td>0.9 to 4.8</td> <td>1.2</td> </tr> <tr> <td>Cervix</td> <td>2</td> <td>1.4</td> <td>0.2 to 4.9</td> <td>0.2</td> <td>6</td> <td>2.7</td> <td>1.0 to 5.8</td> <td>1.1</td> </tr> <tr> <td>Pancreas</td> <td>2</td> <td>1.0</td> <td>0.1 to 3.7</td> <td>0.0</td> <td>5</td> <td>2.9</td> <td>0.9 to 6.7</td> <td>0.9</td> </tr> <tr> <td>Small intestine</td> <td>0</td> <td>0</td> <td>0 to 20.1</td> <td>–0.1</td> <td>3</td> <td>16.2<sup>§</sup></td> <td>3.3 to 47.3</td> <td>0.8</td> </tr> <tr> <td>Thyroid</td> <td>1</td> <td>2.3</td> <td>0.1 to 12.9</td> <td>0.2</td> <td>3</td> <td>5.1<sup>◊</sup></td> <td>1.1 to 15.0</td> <td>0.7</td> </tr> <tr> <td>Prostate</td> <td>4</td> <td>0.7</td> <td>0.2 to 1.9</td> <td>–0.6</td> <td>6</td> <td>1.5</td> <td>0.5 to 3.2</td> <td>0.6</td> </tr> <tr> <td>Bone</td> <td>0</td> <td>0</td> <td>0 to 20.7</td> <td>–0.1</td> <td>2</td> <td>9.0<sup>◊</sup></td> <td>1.1 to 32.5</td> <td>0.5</td> </tr> <tr> <td>Liver</td> <td>2</td> <td>3.4</td> <td>0.4 to 12.5</td> <td>0.6</td> <td>2</td> <td>3.7</td> <td>0.4 to 13.3</td> <td>0.4</td> </tr> <tr> <td>Pleura</td> <td>3</td> <td>6.3<sup>◊</sup></td> <td>1.3 to 18.5</td> <td>1.0</td> <td>2</td> <td>4.4</td> <td>0.5 to 15.9</td> <td>0.4</td> </tr> <tr> <td>Corpus uteri</td> <td>0</td> <td>0</td> <td>0 to 3.1</td> <td>–0.5</td> <td>2</td> <td>1.5</td> <td>0.2 to 5.5</td> <td>0.2</td> </tr> <tr> <td>Testis</td> <td>2</td> <td>1.7</td> <td>0.2 to 6.2</td> <td>0.3</td> <td>1</td> <td>0.6</td> <td>0.01 to 3.3</td> <td>–0.2</td> </tr> </tbody></table></div><div class="graphic_lgnd">Second primary malignancies identified in a cohort of 3564 men and 2234 women treated for Hodgkin lymphoma in Britain from 1963 to 2001.</div><div class="graphic_footnotes">AER: absolute excess risk per 10,000 person-years; CLL: chronic lymphocytic leukemia; SIR: standardized incidence ratio.<br/>* In addition to specified sites, one laryngeal, one gallbladder, two ovarian, two bladder, and two kidney cancers occurred in chemotherapy-only patients, and one laryngeal, one heart, one adrenal, two ovarian, two bladder, and three kidney cancers and one myeloma and three cancers of ill-defined site occurred in mixed-modality patients.<br/>¶ p&lt;0.001.<br/>Δ By coincidence, results for nonmelanoma skin cancer and for breast (female) cancer after chemotherapy plus radiotherapy are the same with one digit after the decimal point. This is not a typographical error.<br/><span class="lozenge">◊</span> p&lt;0.05.<br/>§ p&lt;0.01.</div><div class="graphic_reference">From: Swerdlow AJ, Higgins CD, Smith P, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncol 2011; 29(31):4096-4104. Reprinted with permission. Copyright © 2011 American Society of Clinical Oncology. All rights reserved.</div><div id="graphicVersion">Graphic 57099 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
